coronavirus Archives - Halberd Corporation

Jan 28 2021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

By Halberd|2021-01-28T08:45:25-05:00January 28th, 2021|Featured, Investor News, News|0 Comments

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, ...

Dec 17 2020

Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19

By Admin|2020-12-16T20:11:40-05:00December 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month. The procedure is ...

Dec 10 2020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

By Admin|2020-12-09T21:39:40-05:00December 10th, 2020|Featured, Investor News, News|0 Comments

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...

Oct 13 2020

Arizona State University/Halberd Develop Antibody Against Covid-19

By Admin|2020-10-12T20:32:43-04:00October 13th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: "HALB") reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. ...

Sep 28 2020

Arizona State University/Halberd Pursue Nasal Spray As Covid-19 Preventative/Treatment Based On Children’s Natural Immunity

By Admin|2020-09-27T19:42:54-04:00September 28th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2). Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells. ACE2 (3) is a membrane protein expressed in many ...

Sep 21 2020

Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!

By Admin|2020-09-20T20:34:28-04:00September 21st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will ...

Jul 16 2020

Halberd Advances the Treatment of COVID-19 Utilizing Laser Technology

By Admin|2020-07-21T11:29:21-04:00July 16th, 2020|Featured, Investor News|0 Comments

Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and ...

Jul 1 2020

Halberd Establishes UK Subsidiary

By Admin|2020-07-01T10:06:25-04:00July 1st, 2020|Featured, News|0 Comments

Jackson Center, PA, July 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets. The subsidiary is Halberd Corporation UK, Ltd. William A. Hartman, Chairman, President & CEO of Halberd, stated, “This is the first step in our overall ...

Jun 29 2020

Halberd Method for Treating and Curing the COVID-19 Infection Explained

By Admin|2020-06-28T19:55:51-04:00June 29th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, June 29, 2020 – Halberd Corporation (OTC-PINK: "HALB") today unveils the first of three (3) COVID -19 (Coronavirus) patent pending treatment methods -- the first titled, “Method for Treating and Curing Covid-19 Infection” -- filed with the U.S. Patent and Trademark Office on March 16, 2020. Halberd holds exclusive worldwide license to ...